Nitrendipine Monotherapy in Severe Hypertension

Mroczek, William J.; Burris, James F.
January 1988
Angiology;Jan1988 Part 2, Vol. 39 Issue 1, p81
Academic Journal
Nitrendipine is a new dihydropyridine derivative developed specifically for the treatment of hypertension. Oral nitrendipine was administered to twelve patients with severe hypertension (diastolic blood pressure greater than 114 mm/Hg). All antihypertensive drugs were discontinued at least 72 hours prior to nitrendipine administration. The initial dose of nitrendipine was 5 mgs. orally twice daily which was titrated at 2 to 5 day intervals up to a maximum dose of 40 mgs. twice a day. Average pretreatment blood pressure (�SD) was 194/118 (28/3) mm/Hg and was 191/122 (25/9) mm/Hg standing. After 7 to 10 days of nitrendipine monotherapy, the average blood pressure had decreased to 170/102 (20/9) mm/Hg supine and 167/106 (19/8) mm/Hg standing. Thirty days of nitrendipine therapy resulted in a further decrease of average blood pressure to 159/96 (18/7) mm/Hg supine and 154/99 (12/12) mm/Hg standing. Average su- pine pulse (�SD) increased from 79.0 (13.9) to 90 (15.7) beats/min. after 7�10 days and to 82 (17) beats/min. after 30 days of therapy. The average total daily dose of nitrendipine was 47.5 mgs. after 30 days. Side effects were minimal and the medication was well tolerated by most patients. It was concluded that nitrendipine is a potent and effective antihypertensive agent in patients with severe hypertension.


Related Articles

  • Nitrendipine in the Treatment of Mild to Moderate Hypertension. Moser, Marvin // Angiology;Jan1988 Part 2, Vol. 39 Issue 1, p73 

    Studies have demonstrated that the calcium entry blockers are effective anti-hypertensive drugs, both in severe and in mild to moderately severe hypertension.1.2 Animal and human data have also demonstrated that the reduction in vascular resistance that occurs when these agents are administered...

  • Effects of Antihypertensive Drugs on the Renin-Angiotensin System in Essential Hypertension.  // High Blood Pressure & Cardiovascular Prevention;Sep2010, Vol. 17 Issue 3, p109 

    No abstract available.

  • Felodipine Compared to Nifedipine as "Third-Line Drug" in Resistant Hypertension. Maclean, Derek; Thomson Mitchell, Elizabeth; Sandilands Readman, Ann // Angiology;Nov1986, Vol. 37 Issue 11, p840 

    Felodipine is a new dihydropyridine calcium antagonist, and in hypertension it is a much more effective "third-line" drug than hydralazine. Nifedipine, on the other hand, is the established dihydropyridine calcium antagonist that has been increasingly used to treat hypertension. Information is...

  • Controlling refractory BP.  // Cortlandt Forum;Dec2007, Vol. 20 Issue 12, p12 

    The article provides information about the new drug Azor manufactured by Daiichi Sankyo Co., indicated for hypertension. The drug's pharmacologic class is an antihypertensive with calcium channel blocker + angiotensin II receptor blocker. It may be used as add-on therapy for patients...

  • Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate. Kereiakes, Dean J.; Neutel, Joel M.; Punzi, Henry A.; Jianbo Xu; Lipka, Leslie J.; Dubiel, Robert // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 4, p361 

    BACKGROUND: Most patients with stage 2 hypertension require two or more antihypertensive agents in order to achieve the BP goals recommended in current treatment guidelines. Accordingly, combinations of two drugs with different mechanisms of antihypertensive action are widely used. OBJECTIVE:...

  • Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Flynn, Joseph T.; Pasko, Deborah A. // Pediatric Nephrology;Dec2000, Vol. 15 Issue 3/4, p302 

    The calcium channel blockers (CCBs) are a diverse group of antihypertensive medications with variable pharmacokinetics and clinical effects. Although CCBs have been widely applied to the treatment of hypertensive children, data regarding the pharmacokinetics,efficacy and safety of these agents...

  • The Safety of Nitrendipine in the Treatment of Essential Hypertension--A Review of 61 Clinical Studies. Vanov, Svetislav K.; Pun, Edward F. C.; Taylor, Russell J. // Angiology;Jan1988 Part 2, Vol. 39 Issue 1, p113 

    To assess the safety of the calcium channel blocker nitrendipine, data from 61 clinical studies conducted in the United States and involving 1,245 patients were reviewed. The drug appeared to be tolerated in the majority of patients and the dropout rate was low. The most common side effects...

  • ORAL CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION.  // Monthly Prescribing Reference;Jun2013, Vol. 29 Issue 6, p40 

    Several tables are presented which list oral calcium channel blockers for hypertension including amlodipine, isradipine and nicardipine.

  • Intravenous antihypertensives important in achieving blood pressure control in the perioperative setting.  // Drugs & Therapy Perspectives;Jun2008, Vol. 24 Issue 6, p9 

    There is no one single ideal agent capable of uniformly correcting perioperative hypertension; therefore, a range of antihypertensive agents is currently used in this setting.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics